血清抗磷脂酶A2受体抗体在特发性膜性肾病诊断和治疗中的应用研究进展  

Research progress of serum Anti-phospholipase A2 receptor Antibody in the diagnosis and treatment of Idiopathic Membranous Nephropathy

作　　者：康可馨 Kang Kexin(Tianjin Medical University General Hospital,Tianjin 300052,China)

机构地区：[1]天津医科大学总医院,天津300052

出　　处：《首都食品与医药》2025年第3期24-27,共4页Capital Food Medicine

摘　　要：在当前全球慢性疾病负担日益增加的背景下,特发性膜性肾病(Idiopathic Membranous Nephropathy,IMN)作为一种常见的慢性肾脏病,其诊断和治疗一直是肾脏病学领域的研究热点.IMN的确切病因尚不明确,但越来越多的证据表明抗磷脂酶A2受体抗体(anti-PLA2R antibodies)在IMN的发病机制中扮演着关键角色,且与疾病的活动及预后相关,细化到可以制定患者个体化的治疗方案.近些年抗磷脂酶A2受体抗体的检测得到了一定普及,也被越来越多的医生和患者所认可.本文通过搜集近期国内外的研究结果,阐述抗磷脂酶A2受体抗体在膜性肾病发生机制、诊断和治疗以及预后中的作用.In the context of the increasing global burden of chronic diseases,Idiopathic Membranous Nephropathy(IMN)is a common chronic kidney disease,and its diagnosis and treatment have always been a research hotspot in the field of nephrology.The exact etiology of IMN is still unclear,but more and more evidences show that anti-PLA2R antibody plays a key role in the pathogenesis of IMN,and are related to the activity and prognosis of the disease,which can be refined to develop individualized treatment plans for patients.In recent years,the detection of anti-PLA2R antibody has been popularized to a certain extent,and has been recognized by more and more doctors and patients.This article aims to elaborate the role of anti-PLA2R antibody in the pathogenesis,diagnosis,treatment and prognosis of membranous nephropathy by collecting recent research results at home and abroad.

关 键 词：抗磷脂酶A2受体抗体 特发性膜性肾病 研究进展 

分 类 号：R692[医药卫生—泌尿科学]